KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Edwards Lifesciences (EW) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to 19.77%.

  • Edwards Lifesciences' EBITDA Margin fell 61100.0% to 19.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.23%, marking a year-over-year decrease of 23300.0%. This contributed to the annual value of 25.35% for FY2024, which is 7800.0% down from last year.
  • Latest data reveals that Edwards Lifesciences reported EBITDA Margin of 19.77% as of Q3 2025, which was down 61100.0% from 26.84% recorded in Q2 2025.
  • Edwards Lifesciences' EBITDA Margin's 5-year high stood at 45.99% during Q4 2022, with a 5-year trough of 19.77% in Q3 2025.
  • For the 5-year period, Edwards Lifesciences' EBITDA Margin averaged around 29.3%, with its median value being 28.16% (2021).
  • As far as peak fluctuations go, Edwards Lifesciences' EBITDA Margin surged by 577400bps in 2021, and later tumbled by -186000bps in 2023.
  • Edwards Lifesciences' EBITDA Margin (Quarter) stood at 28.16% in 2021, then skyrocketed by 63bps to 45.99% in 2022, then plummeted by -40bps to 27.38% in 2023, then fell by -18bps to 22.56% in 2024, then decreased by -12bps to 19.77% in 2025.
  • Its last three reported values are 19.77% in Q3 2025, 26.84% for Q2 2025, and 27.95% during Q1 2025.